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Abstract
We present GStream, a method that combines genome-wide SNP and CNV genotyping in the Illumina microarray platform
with unprecedented accuracy. This new method outperforms previous well-established SNP genotyping software. More
importantly, the CNV calling algorithm of GStream dramatically improves the results obtained by previous state-of-the-art
methods and yields an accuracy that is close to that obtained by purely CNV-oriented technologies like Comparative
Genomic Hybridization (CGH). We demonstrate the superior performance of GStream using microarray data generated from
HapMap samples. Using the reference CNV calls generated by the 1000 Genomes Project (1KGP) and well-known studies on
whole genome CNV characterization based either on CGH or genotyping microarray technologies, we show that GStream
can increase the number of reliably detected variants up to 25% compared to previously developed methods. Furthermore,
the increased genome coverage provided by GStream allows the discovery of CNVs in close linkage disequilibrium with
SNPs, previously associated with disease risk in published Genome-Wide Association Studies (GWAS). These results could
provide important insights into the biological mechanism underlying the detected disease risk association. With GStream,
large-scale GWAS will not only benefit from the combined genotyping of SNPs and CNVs at an unprecedented accuracy, but
will also take advantage of the computational efficiency of the method.
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Introduction
Over the last years, Genome-Wide Association Studies (GWAS)
using microarray-based technology have played an important role
in the identification of common genetic variations and their
relationship with disease susceptibility [1,2,3,4]. Genotyping
microarrays [5] have enabled this success through the parallel
genotyping of thousands of Single Nucleotide Polymorphisms
(SNPs), capturing most of the common variation in the human
genome. Very recently, the new generation of microarrays have
integrated the extensive knowledge revealed by the 1KGP [6] and,
together with the decreasing costs of this technology, are now
allowing the use of the GWAS approach to the association of rare
genetic risk variants or more complex human traits.
In addition to SNPs, Copy Number Variants (CNVs) have
shown to play an important role in disease susceptibility [7]. CNVs
are relatively large (.500 bp) genomic variations and include
deletions, tandem duplications and insertions [8]. Recent studies
based either on specific CGH arrays or genotyping microarrays
have demonstrated the importance of CNVs due to their global
contribution to the human genome variation, their functional
impact and their role in human disease [7,9,10,11,12,13,14].
Some of these reference studies have contributed to elaborate a
map of regions containing highly polymorphic CNVs called Copy
Number Polymorphisms (CNPs) [9,10,15]. These common
variations have appeared as a significant area of interest, since
they segregate in the population at an appreciable frequency and
their analysis over big sample collections could potentially lead to
significant disease risk associations.
The development of the two mentioned technologies (CGH
arrays and genotyping microarrays) for high throughput CNV
screening has prompted the inclusion of CNVs in GWAS studies
[16,17,18,19]. When comparing both technologies, genotyping
microarrays offer the practical advantage of obtaining at the same
time SNP and CNV genotype data. However, there is still a major
need to develop methods that can best deal with the signal-to-noise
ratio deficiencies and genomic coverage of genotyping microarray
data when attempting to identify and quantify CNVs. So far, most
of the commonly used methods for CNV detection and genotyping
at the genome-wide scale [20,21,22] are based on independent
per-sample analyses that use summarized measurements relative to
a reference set of samples. This type of approach has proven to
work well for large genomic variations, but it fails to use the
powerful information generated by analyzing multiple samples,
leading to high false negative rates with small CNVs [23].
In this study we present GStream, a method for SNP and
CNV/CNP genotyping that is tailored to GWAS objectives.
GStream integrates a substantially improved version of our
previous CNV calling software CNstream [24]. Our new method
achieves a superior accuracy in both SNP and CNV genotyping
compared to well-established methods. Indeed, GStream obtains
an unprecedented accuracy within CNV regions, with a perfor-
mance close to that obtained from purely CNV-oriented
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e68822
technologies like CGH arrays. All these improvements have been
quantitatively compared against previous state-of-the-art methods
and accurately assessed using different Illumina genotyping
microarrays together with publicly available SNP [25] and CNV
[9,10,15] reference datasets based on Next-Generation Sequenc-
ing (NGS), CGH array and genotyping microarray technologies.
Finally, the computational efficiency of the method has been
optimized, enabling the large-scale SNP and CNV analyses to be
performed in a short amount of time.
In addition to presenting this new method and demonstrating its
superior performance over reference datasets, we have also
performed different relational analyses concerning previously
known risk loci. Using GStream we have been able to identify,
for the first time, several CNVs in strong linkage disequilibrium
(LD) with risk-associated SNPs [26] as well as CNVs spanning
disease-associated genes [27]. Together, these results could reveal
important insights into the causality of these disease risk
associations.
Materials and Methods
We first introduce the Illumina BeadChip microarrays and
describe the algorithms for SNP and CNV genotyping. Next, we
provide information about the datasets used in this study and the
Figure 1. GStream method for SNP genotyping. This figure shows how GStream genotyping method works on two example markers, the first
one representing a typical marker capturing a SNP (A and B) and the second one capturing both a SNP and a CNV (C and D). The leftmost graphs
show the effects of the normalization procedure for the two markers, where the dotted blue lines enclose the ranges where candidate homozygotes
and heterozygotes are identified in order to compute the scaling factors for each channel (black points over the axes). The rightmost graphs give an
overview of the genotyping procedure: Upper subfigures represent the scaled BAF probability density function with the solid vertical lines setting the
identified genotype centres, the dotted vertical lines setting the genotype limits and the horizontal lines representing the sequential search of
genotype cluster peaks. Medium and lower subfigures represent genotype calls and quality call scores respectively.
doi:10.1371/journal.pone.0068822.g001
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implemented metrics for evaluating SNP and CNV genotyping
accuracy. Finally, we describe the methods used for the CNV
association studies that we have run using the GWAS catalog [26]
and the OMIM [27] databases.
Illumina BeadChip Data
Illumina BeadChips have been largely used in large-scale
genome-wide association studies and are based on the Infinium
assay technology [28]. This type of genotyping array consists on
hundreds of thousands of probe pairs designed to capture genomic
variation at the SNP and CNV level. In each probe pair, each
probe has been designed to specifically bind one of the two SNP
alleles (i.e. alleles A and B) generating a pair of fluorescence
intensities. These signals are then measured and processed in order
to infer the presence or absence of these alleles in each sample.
GStream software uses these raw measurements to extract SNP
and CNV genotypes for each sample at each probe pair. From
here on, fluorescence measurements of alleles A and B will be
called channel A and B intensities and samples will be categorized
at each SNP as homozygotes (i.e. AA or BB) or heterozygotes (i.e.
AB).
GStream method for SNP genotyping
Before identifying the clusters corresponding to the AA, AB and
BB genotypes at each probe, raw intensity data of each probe must
be normalized in order to equalize the overall sample intensity
distribution at each channel (Figure 1). This step is crucial since
the sensitivity differences of each probe and channel can lead to
bias affecting the genotyping performance. The method used by
GStream is based on the scaling correction used by Peiffer et al.
[29]. In this method, the intensity centroids of a set of pre-
computed AA and BB candidate homozygote samples are
identified and used to scale channel A and B intensities. However,
GStream adds two modifications in order to improve the
normalization in those cases involving probes capturing both
SNP and CNV variation. First, instead of using candidate
homozygote intensity centroids, the scaling parameter is computed
by weighting the candidate homozygotes intensity distributions
(the higher the intensity, the higher the weight) and by finding the
maximum over the resulting curve (Figure S1). This modification
helps GStream to better deal with the particularities of intensity
distributions coming from probes within CNV regions. The
second modification introduced by GStream uses heterozygote
intensity data when no homozygote candidates are found, thus
helping to better deal with probes capturing low MAF SNPs.
Once the intensities from both A and B channels have been
normalized, GStream proceeds to identify the clusters correspond-
ing to each SNP genotype (i.e. AA, AB and BB). Developing an
accurate SNP genotyping method is crucial not only for SNP
analysis itself, but also because GStream CNV genotyping method
uses this information to improve the accuracy of the CNV call.
GStream applies the following procedure to assign a SNP
genotype to each sample at each marker:
1. Channel A and channel B intensities from the analyzed marker
are transformed to B allele frequencies (BAF) and absolute
intensities [29].
2. Absolute intensities are used to detect samples without any
allele (homozygous deletions) which are characterized by very
low intensities at both channels. In order to compute the
absolute intensity threshold between homozygous deletion
samples and the other samples, the absolute intensities are
sorted and then differences between each pair of consecutive
intensities are computed. If high intensity differences are found
within the expected threshold range ([0, 0.5]), the zero-
threshold is fixed to the corresponding intensities (Figure S2).
3. The BAF probability density function (PDF) is estimated by
computing the scaled histogram of all the sample BAF values.
Peaks over this PDF corresponding to genotype clusters will be
identified sequentially starting by the peak generated by the
major allele frequency homozygote cluster. The algorithm
establishes a minimum separation between peaks in order to
assign them to different genotype clusters and it stops when
three peaks have been found or when no more peaks are found.
Once genotype peaks have been found, genotype limits are
computed by finding the PDF minimum between each
consecutive pair of centres (Figure 1). These limits will define
the BAF intervals assigned to each genotype and each sample
will be genotyped accordingly to them.
4. If the number of genotype peaks identified is less than three,
each genotype cluster is re-analyzed with a better resolution
(i.e. increasing the number of histogram bins to estimate the
BAF PDF) in order to identify sub-clusters corresponding to
different genotypes. This procedure avoids common errors
seen in others algorithms where, for example, genotypes of
SNPs with highly discordant sensitivities at each channel are
incorrectly assigned.
5. Finally, a global genotyping quality score and an individual
score for each sample genotype are computed (Figure 1). The
global score is proportional to the standard deviation mean of
the BAF values assigned to each genotype and the individual
score corresponds to the distance between the sample BAF
value and its corresponding genotype peak divided by the
distance between genotype centres.
Both genotypes and quality control measurements for each
sample are extracted by GStream to the output files. This
information is also required by the CNV genotyping method,
which is based both on the normalized channel intensities and the
SNP genotype information. Further algorithm details are given in
Text S1.
GStream method for CNV genotyping
CNV identification and genotyping is one of the principal
contributions of GStream to the current state-of-the-art micro-
array genotyping methodology, clearly outperforming previous
approaches. Although this method has been based on our previous
CNstream method [24], multiple changes have been introduced in
order to improve performance and computational efficiency.
GStream uses normalized intensities and SNP genotypes
computed in the SNP genotyping stage to identify the presence
of deletions and amplifications characterized by variable clustering
patterns on the intensity data (i.e. high frequency CNVs) or by
slight deviations from the diploid distribution (i.e. low frequency
CNVs).
One of the improvements incorporated in the algorithm is that
each SNP genotype cluster is independently analyzed taking only
into account the intensity channel that carries valuable informa-
tion. This way, the CNV algorithm is divided in four parallel steps
(Figure 2A):
i. Analysis of channel A intensities from the samples previously
genotyped as AA homozygotes.
ii. Analysis of channel B intensities from the samples previously
genotyped as BB homozygotes.
iii. Analysis of channel A intensities from the samples previously
genotyped as heterozygotes (i.e. AB).
GStream: Improving SNP and CNV Coverage on GWAS
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Figure 2. GStream method for CNV genotyping. (A) Each CNV analysis is divided in four independent sets where the number of allele copies
per channel intensity is estimated. Here, the homozygote intensities over its respective informative channels (upper rightmost and leftmost graphs)
are fitted with a two-component model (in this case, capturing a deletion) while heterozygote intensities over each channel are better fitted with a
one-component model (upper centre graphs). Lower graphs show the intensity distributions (solid black lines) together with the corresponding copy
number score (red points) assigned to each sample. AA homozygotes are mostly classified as deletions (scores near to 1), BB homozygotes are
divided into diploids (scores,2) and deletions (scores,1) while heterozygotes are classified as diploids (i.e. one allele detected at each channel). (B)
Final representation of the analyzed probe where points represent samples and colour their relative copy number scores. SNP and CNV genotypes are
assigned along the BAF and the intensity axis respectively.
doi:10.1371/journal.pone.0068822.g002
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iv. Analysis of channel B intensities from the samples previously
genotyped as heterozygotes (i.e. AB).
As well as dividing the analysis in four independent steps, the
algorithm is based on the following assumptions:
i. Homozygous deletions (0 allele copies) are previously
detected during the SNP genotyping stage.
ii. Due to the technical limitations of genotyping microarrays,
the intensity measurements show a saturation effect when
amplifications are found. For this reason, intensity clustering
patterns corresponding to amplifications are very rare and
hard to detect unless they span multiple probes [30].
iii. Samples categorized as homozygote samples (i.e. AA and BB)
can correspond to hemizygous deletions (i.e. A and B) or
amplifications (i.e. AA+ and BB+). Due to the saturation
effect the algorithm does not stratify amplifications by the
number of allele copies.
iv. Samples characterized as heterozygotes (i.e. AB) can have
two or more copies (i.e. AB, AAB, ABB …). The total
number of copies can be inferred by independently
computing the number of copies of each allele and then
adding the results for each sample.
Below we describe the procedure for determining the CNV
genotypes from the set of channel intensities of each one of the
four analysis steps.
Model selection. For each SNP genotype, the algorithm
starts identifying clusters over the channel intensities that carry the
corresponding allele information (i.e. channel A for AA homozy-
gotes, channel B for BB homozygotes and both channels for AB
heterozygotes). Due to the mentioned saturation effects, it is very
uncommon to observe more than two intensity clusters in
microarray data and, for this reason, only two models will be
fitted to the intensity data: a one- and a two-component Gaussian
mixture model (GMM). The first one will be fitted using the mean
and the variance of all the intensities while the second one will be
fitted using the Expectation-Maximization algorithm [31]
(Figure 2A). A set of requirements in order to select the second
model have been carefully developed and only if all of them are
accomplished, the two-component model (indicating a pattern
corresponding to a common CNV) will be selected (Figure 2A).
Component labeling. If the two-component model has been
selected, a copy number category will be assigned to each one of
the two components. As no prior knowledge is available to assign
the two components either to a deletion pattern (i.e. CN=1 and
CN=2) or to an amplification pattern (i.e. CN=2 and CN=3), a
disambiguation method is necessary. GStream bases the compo-
nent labelling both on the relative weight of each component (i.e.
proportional to the copy number frequency) and on the presence
of homozygous deletions (Figure S3A). When the one-component
model has been selected, the component will be labelled by default
to CN=2 (i.e. diploid), which is assumed to be the most common
state.
Outlier identification and CNV scoring. Outlier identifi-
cation is intended to capture low frequency CNVs that are not
captured by a two-component GMM and is based on identifying
samples showing high or low deviations from the intensity
distributions defined by the selected model. CNV scoring assigns
to each sample i a score S between 0 and 3 depending on its copy
number posterior probabilities (Figure S3B). At the end of this
step, GStream has obtained a CNV score for all the samples that
allows the identification of deletions and amplifications as well as a
quantification of the reliability of the assignment (Figure 2B).
Additional algorithm details are given in Text S1.
Microarray data from HapMap samples
In order to evaluate and compare the performance of GStream
SNP and CNV genotyping methods we have used raw Illumina
microarray data from HapMap samples available at the Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/)
[32] (Table 1). This data has been also used as the input of state-of-
the-art SNP and CNV genotyping algorithms in order to extract
accurate comparison measures as well as to ensure a performance
assessment independent from the technical biases of the raw data.
Only markers having available NCBI Build 37 mapping
information were kept for further analysis.
SNP genotyping performance evaluation and
comparison with previous methods
Golden standard genotypes. In order to correctly evaluate
the SNP genotyping algorithm performance, a set of independent
and high-quality genotype calls is required. The genotype calls of
HapMap samples have been established as a golden standard
commonly used in the literature for performance evaluation of
SNP genotyping methods. These calls are available for download
through the online HapMap tool HapMart (http://hapmap.ncbi.
nlm.nih.gov/biomart). For this study, we downloaded the
genotypes corresponding to the samples having available micro-
array data and used them as the golden standard. SNPs used for
performance evaluation were chosen in order to fulfil three
criteria: (i) to have available Build37 mapping information, (ii) to
be present both in the analyzed microarray platform and in the
golden standard HapMap dataset, and (iii) to have concordant
reference alleles both in the microarray and in the golden standard
annotations (Table 1).
Algorithms. GStream SNP genotyping accuracy has been
evaluated and compared with three methods: (i) GenoSNP [33]
which is a well-known genotyping algorithm based on a within-
sample approach; (ii) GenCall, which is the proprietary (Illumina,
San Diego, US) algorithm [34], and it is used by the vendor
genotyping software; (iii) M3 [35], which is a recently published
method for SNP genotyping that re-analyzes the data in order to
increase the accuracy over the low MAF SNPs and has shown to
have increased performance.
Copy number genotyping performance evaluation
Copy number evaluation was performed at two levels:
Evaluation of the GStream ability to detect structural variation
obtained from the 1000 Genomes Project [6] next-generation
sequencing (NGS) data and evaluation and comparison of CNV
population association results using different algorithms and
golden standard calls from three recently published studies
[9,10,15]. Below we describe materials, methods and metrics used
for this two-stage evaluation.
Evaluation of CNV genotyping accuracy over the 1KGP
Structural Variants. In order to test the ability of GStream to
detect copy number variation, we have used the HumanOmni1-
Quad GStream calls and a golden standard dataset from a public
release of the 1KGP. HumanOmni1-Quad platform was chosen
due to its highest coverage and resolution which allowed an
evaluation over a major number of loci. The golden standard
dataset consisted of the last variant call files that have been
released by the 1KGP (version v3_20110521, ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/release). From all the variants
included in the 1KGP release we chose those that corresponded to
structural variations (i.e. CNVs) and we filtered out variants with a
GStream: Improving SNP and CNV Coverage on GWAS
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MAF lower than 2% within all the populations. The resulting set
included 2,531 structural variants (SV) with their respective calls
over N= 353 unrelated HapMap samples. From these 2,531 loci,
1,956 are covered by HumanOmni1-Quad markers and GStream
calls were available for 149 out of the 353 1KGP samples, which
jointly formed the final evaluation set.
The evaluation procedure consisted of finding the markers
whose GStream calls are in maximum LD with each SV:
max
i[Sk
r2 CNi,SVkð Þ
 
where Sk is the set of microarray markers within the region
spanned by the SV, CNi is the copy number genotypes assigned by
GStream at marker i and SVk is the 1KGP calls for the analyzed
SV k.
Evaluation of the power to detect genome-wide
associations over CNV markers and comparison with
previous methods. The objective of this section is to evaluate
the power to detect CNV associations and to compare GStream
performance with other well-known methods. This comparison
was performed using Human1M-Duo and HumanOmni1-Quad
platforms. Using these two platforms also allowed an assessment of
the specific platform power to detect CNV associations, comparing
platforms with (i.e. HumanOmni1) and without (i.e. Human1M) a
specific design to cover CNV.
The genome-wide association study over CNV markers was
performed at the population level aiming to identify CNVs
significantly associated to specific populations and comparing the
association statistics with those obtained from golden standard
datasets.
The CNV algorithms used are described below:
i. PennCNV [22] is one of the most frequently used methods
for analyzing CNVs using Illumina microarrays. This
software implements a CNV estimation method based on
Hidden-Markov-Models (HMM), in which copy number calls
are performed sample by sample by analyzing the sample
LRR (i.e. absolute intensity) and BAF values at each marker.
Default settings were used in the analysis of the available
HapMap samples generating the PFB file (i.e. population
frequency of B allele) from their genotyping data.
ii. QuantiSNP is also one of the well-known methods for CNV
analysis over Illumina microarrays. It is based on an
Objective Bayes Hidden-Markov Model that is used to set
certain hyperparameters in the HMM priors (for details see
Colella et al. [20]). Default settings were used in this analysis
with the provided Infinum HD parameter files and the local
GC content files.
iii. CNstream [24] was also evaluated in order to demonstrate
how our new method overperforms the previous one due to
the major critical modifications introduced.
Association statistics obtained by each algorithm were com-
pared with those obtained from three recently published reference
studies:
i. The first dataset was obtained from a study published by
McCarroll et al. [15]. In this study a hybrid genotyping array
was designed to simultaneously measure SNPs and CNVs.
Almost half (N= 1,320) of the targeted CNV regions were
observed in multiple unrelated individuals and were defined
as CNPs. From this set of CNPs we selected the autosomal
CNPs (N= 1,292) over the 270 HapMap samples as the first
golden standard dataset.
ii. We used the data published by Conrad et al. [10] as the
second golden standard dataset. In this study, an Agilent
CGH based array was used to generate a map of CNVs
greater than 443 base pairs. For 4,978 of these CNVs
reference genotypes from 450 HapMap samples are available
to download. We used the corresponding sample calls for all
the 4,899 autosomal CNVs.
iii. The last dataset used for CNV performance evaluation was
obtained from the results published by Campbell et al. [9]. In
this study a custom Agilent CGH microarray targeting
regions of known CNPs was designed and evaluated over
HapMap samples of diverse ethnic backgrounds. For this
analysis we used the published discrete CNV calls of
polymorphic loci represented in the reference genome
assembly (N= 874) for the 487 HapMap samples included
in the analysis.
In order to provide a measure of genome-wide association
power, pairwise population-association tests (CEU:YRI,
CEU:CHBJPT and YRI:CHBJPT) were performed using the
calls from the three golden standard datasets. Loci that either were
not covered by the microarray platform or did not obtain
significant associations (P-value,0.05) in any population test
(Table 2) were filtered out. Chi-square test P-values were then
computed at each locus and compared to those obtained using the
calls of the four methods across the markers covering the locus.
For each algorithm, the marker obtaining the best result across the
region was selected for comparison.
Copy number variation and disease susceptibility
Using microarray data to accurately extract information from
copy number variation can be particularly relevant when trying to
identify all the type of variants that convey risk to disease
susceptibility. Using two available catalogues of disease genomic
Table 1. Public microarray data used in this study.
PLATFORM POPULATION SAMPLES GEO ACCESSION AUTOSOMAL MARKERS EVALUATION
Human610-Quad CEU/CHBJPT/YRI 73/75/77 GSE17205/GSE17206/GSE17207 596528 568182
Human660W-Quad CEU/CHBJPT/YRI 89/89/89 GSE17208/GSE17209/GSE17210 638582 552529
Human1M-Duo CEU/CHBJPT/YRI 89/90/90 GSE16894/GSE16895/GSE16896 1141594 1058827
HumanOmni1-Quad CEU/CHBJPT/YRI 88/89/90 GSE17197/GSE17201/GSE17203 1103791 882445
The used microarray data comes from four different Illumina BeadChip platforms and the sample data comes from three HapMap populations. The total number of
autosomal markers and the number of markers used for SNP genotyping evaluation are shown.
doi:10.1371/journal.pone.0068822.t001
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associations we have used two different approaches to demonstrate
the joint capacity of microarray platforms and the GStream
method to identify new CNV disease associations. The two
analysis explained here have been performed using the CNV calls
inferred by GStream over the HapMap samples genotyped with
the Illumina HumanOmni1-Quad platform.
Catalog of published genome-wide association
studies. Since microarray genotyping platforms became avail-
able, a large number GWAS have allowed the discovery of
important SNP-trait associations. However, some of these SNPs
have limited or no known functional impact. In these cases, the
possibility that they act as proxies of other types of variations (i.e.
CNVs [36,37]) with a deeper functional impact is more likely.
In order to identify putative causal CNVs we have analyzed the
LD patterns between all the trait-associated SNPs reported by the
catalog of published genome-wide association studies (http://
www.genome.gov/gwastudies) [26] and the CNV microarray
markers detected over the HumanOmni1-Quad platform. Trait-
associated SNP genotypes were extracted from the 1KGP data
reported previously and CNV genotypes were called with
GStream. All the HumanOmni1-Quad markers that presented a
non-diploid frequency greater than 1% (CNV markers) were
included in the analysis (NCNV=90,892) together with the 7,571
trait-associated SNPs.
The conditions used for selecting the candidate SNP-CNV pairs
where the CNV could provide new functional information on the
reported association are described below:
i. Distance between the SNP and the CNV markers not greater
than 50 kb.
ii. Correlation coefficient r2 greater than 0.7 in any of the three
analyzed HapMap populations (CEU, YRI and CHB+JPT).
iii. Distance between the CNV marker and the nearest gene not
greater than 100 kb or CNV marker spanning binding
transcription factor regions as defined by the Transcription
Factor ChIP-seq track on the UCSC browser [38].
From the 7,571 trait-associated SNPs, 382 were paired with one
or more CNV markers fulfilling these conditions. A final set of 333
SNP-CNV pairs was obtained after filtering out repeated
associations of SNPs with the same trait by different GWAS
studies.
CNV overlapping analysis with disease-related
genes. In this second approach, we examined the CNV variants
called by GStream spanning genes known to be involved in disease
based on the OMIM database (http://www.omim.org) [27]. In
order to characterize CNVs with a high probability of conveying
functional effects on the disease-related OMIM genes we set
multiple strict selection criteria:
i. From the initial set of CNV markers (NCNV=90,892) only
those located less than 15 kb away from an OMIM gene and
with at least two more CNV markers covering this gene were
selected (NCNV=5,836).
ii. We defined CNV loci as sets of three or more nearer CNV
markers (i.e. distance between them not greater than 5 kb) in
high LD (r2.0.7) spanning the same OMIM gene. After
applying this filter we obtained a final set of 212 CNV loci
spanning OMIM genes.
iii. Finally, when more than one CNV locus spanned the same
gene, only the one showing the greatest r2 measurements
between its CNV markers was kept for further analysis.
The final set of candidates consisted of 149 CNV loci spanning
disease-related OMIM genes.
Software availability
An executable version of GStream along with the documenta-
tion and example data files can be freely downloaded from our
website http://www.urr.cat/GStream. This web site also provides
regularly updated results of new CNV associations within known
human risk loci identified with this method.
Results
Performance assessment of SNP genotyping
For each available Illumina platform, the golden standard
genotype calls were compared with the calls generated by
GStream, GenoSNP, GenCall and M3 software tools. The global
accuracy results over autosomal SNPs (Table 3) show a moderate
improvement for GStream with respect to GenoSNP and a
substantial improvement with regards to GenCall and M3
methods. GenCall performed very well when ‘‘non-called’’
genotypes where discarded, but its global performance decreased
due to its low call rate. M3 algorithm could only be evaluated over
the Human610-Quad and the Human660W platforms due to
code incompatibilities with the Human1M-Duo and the Huma-
nOmni1-Quad platforms. Although the improvement of GStream
SNP-genotyping method regarding its competitors may not appear
very high, they can represent a significant improvement from an
absolute point of view (i.e. the accuracy differences when using
HumanOmni1-Quad would be equivalent to a gain of 2,300
completely genotyped SNPs). Chromosome X genotyping accu-
racy was also evaluated, obtaining a similar decrease in
performance (,0.5%) for all the algorithms and maintaining the
accuracy differences between algorithms.
The second performance test consisted of computing the global
accuracies at different levels of drop rate, where drop rate refers to
the percentage of markers which are removed from the accuracy
Table 2. CNV regions for each dataset and platform used to evaluate the power to detect genome-wide associations.
HumanOmni1-Quad Human1M-Duo
Study Technology NCNVRs NCNVRs covered NASSOCS (P-value,0.05) NCNVRs covered NASSOCS (P-value,0.05)
McCarroll Affymetrix 1292 1290 929 1288 927
Campbell Agilent CGH 874 874 962 873 962
Conrad Agilent CGH 4899 4899 3659 4899 3671
NCNVR refers to the number of CNV loci selected from each study. Coverage with at least one marker within the CNV loci of both platforms is very similar although the
marker density differs considerably. NASSOCS column refers to the total number of associated regions for the three population tests detected over the golden standard
calls.
doi:10.1371/journal.pone.0068822.t002
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computation based on low call confidence measures (as defined by
Ritchie et al. [39]). When markers are discarded by low global
marker quality score - a common filtering procedure in GWAS
quality control steps - GStream reaches the best performance for
all the evaluated drop rates (Figure 3). Furthermore, the difference
in accuracy between low and high drop rates is much lower on
GStream, which implies a robust genotyping performance, even
for those markers with lower quality scores. The low accuracy
values obtained using GenCall at low drop rates can be explained
from its low call rate (i.e. only when the drop rate exceeds the
uncall rate, GenCall performance is comparable to the other
algorithms, otherwise uncalled SNPs are included in the perfor-
mance evaluation). When discarding markers by low quality
sample calls, the results show a similar pattern but with reduced
accuracy differences between the algorithms (Figure S4A). These
results place GStream as the best option for SNP genotyping, since
its genotyping accuracy reaches its maximum at lower drop rates
compared to the other algorithms.
We also examined the performance with respect to the minor
allele frequency (MAF, Figure S4B). Two key conclusions result
from this analysis: First, probes capturing rare SNPs (MAF,0.05)
showed a slight accuracy reduction (,0.5%) on all the platforms
and algorithms tested and, second, GStream accuracy gain with
respect to the other algorithms was practically independent of the
SNP MAF.
Finally, we tested the effect of sample size on GStream accuracy
(Figure S4C). The computed accuracy was compared to the
accuracies obtained for the other algorithms when using all the
Human610-Quad samples (N= 225). However, even for sample
sizes as low as N=20, the global accuracy of GStream is clearly
higher than the accuracies obtained by the other algorithms, even
if the highest sample size (N= 225) is used, demonstrating the
superior sensitivity of GStream genotyping algorithm.
Performance assessment of CNV genotyping
1KGP Structural Variants. SV calls from 1KGP for 149
unrelated HapMap samples (i.e. NCEU= 32, NYRI = 37 and
NCHBJPT = 80) were compared with their respective GStream calls
in order to measure the ability to detect this type of variation using
GStream on microarray data. For each SV (N=1,956), we
computed the CNV genotyping accuracy by finding the maximum
LD measurement between its golden standard calls and the
GStream calls over the HumanOmni1-Quad markers covering the
region. The results showed a high correlation between GStream
and 1KGP calls: 75.7% of the SVs were captured by GStream
with an r2.0.8, 18.3% with an r2,0.8 and only 6.0% were not
detected by GStream (Figure 4A).
Once demonstrated the power of GStream to capture these
variants, we examined the variance of the LD measurements
across the markers spanning the same SV loci. This analysis was
stratified by the maximum LD measurement of the SV as
explained in the previous paragraph. From the results (Figure 4B)
we can conclude that the calls inferred over probes spanning the
same structural variant obtain consistent values with a slight
variance due to the quality differences across markers.
Finally, we also observed that the calling performance slightly
decreases with the frequency of the analyzed SVs due to an
increment of the r2 interquartile ranges (Figure 4C). Nevertheless,
lower quartiles exceeded r2 = 0.7 within almost all the frequency
ranges tested.
Table 3. Global accuracy results for SNP genotyping.
Method call rate (%) accuracy (%) global accuracy (%) CNstream differential (%)
Human610-Quad
GStream 99.952 99.798 99.750
GenoSNP 100.000 99.577 99.577 20.173
GenCall 96.724 99.868 96.596 23.154
M3 99.584 99.585 99.171 20.579
Human660W-Quad
GStream 99.990 99.804 99.794
GenoSNP 100.000 99.650 99.650 20.144
GenCall 95.411 99.879 95.295 24.499
M3 99.798 99.635 99.434 20.360
Human1M-Duo
GStream 99.970 99.768 99.738
GenoSNP 100.000 99.561 99.561 20.177
GenCall 98.024 99.825 97.853 21.885
M3 NA NA NA NA
HumanOmni1-Quad
GStream 99.971 99.671 99.643
GenoSNP 100.000 99.435 99.435 20.208
GenCall 97.083 99.747 96.838 22.805
M3 NA NA NA NA
Call rate refers to the percentage of called genotypes while the accuracy is computed as the number of correct genotypes over the number of called genotypes. Global
accuracy summarizes both measurements by computing the number of correct genotypes over the total number of genotypes available within the golden standard
dataset.
doi:10.1371/journal.pone.0068822.t003
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We conclude this section by stressing the power of GStream to
detect structural variation identified with more advanced technol-
ogies (i.e. NGS), obtaining CNV calls with an r2.0.8 over 75.7%
of the 1KGP variants and calls with an r2.0.9 over 62.3% of the
variants.
Genome-wide CNV association study. In order to evaluate
the power to detect CNV associations we have performed a
Figure 3. Evaluating SNP genotyping performance. Plots comparing SNP genotyping algorithms for each microarray platform are tested. The
vertical axis represents the percentage of SNPs that are excluded from the accuracy calculation by the lowest quality score criteria. GStream
performed better at all the drop rate levels in all the platforms. A high decrease in performance is observed for GenCall when drop rate values are
lower than its uncall rate (i.e. ,2% in Human610Quad).
doi:10.1371/journal.pone.0068822.g003
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pairwise association study between three HapMap populations
using golden standard data from three reference studies [9,10,15].
The association statistics obtained by the golden standard calls
were compared with those obtained by GStream, CNstream1,
PennCNV and QuantiSNP across two microarray platforms,
HumanOmni1-Quad and Human1M-Duo. These two platforms
were chosen since they represent the first and the second
generation of the Infinium HD genotyping microarrays, which
mainly differ by the inclusion of additional probes to obtain a
better coverage of CNV loci. These differences (Figure S5) are
clearly visible and the coverage analysis over the CNV regions
defined by the three published studies showed how the marker
density is doubled within these CNV regions between the first and
the second platform generations (i.e. from 10 to 20 markers/
region).
The main metric used to test CNV methods was the 2log10P-
value ratio between the association values obtained by the calls of
each method and those obtained from the golden standard calls.
Under this metric, ratios near 1 represent a good performance for
the method since the obtained association P-value is very similar to
the golden standard. A performance summary statistic was
computed as the percentage of 2log10P-value ratios giving values
between 0.9 and 1.1 over all the associated CNV loci.
Firstly, the obtained results showed a high performance
decrease in the detection of CNV associations when comparing
HumanOmni1-Quad results with Human1M-Duo (Table 4). This
loss was common to all the methods tested but PennCNV and
QuantiSNP showed a higher percentage decrease (,70%) than
GStream and CNstream (,40%). When comparing GStream to
the other state-of-the-art methods, results showed a major
performance gain on all the golden standard sets and on both
microarray platforms. Results for each platform are described
below.
HumanOmni1-Quad results show that GStream is able to
precisely capture an average of 23.6% more associated loci than
the other methods (Table 4) and that the number of false negatives
(Figure S6) decreased considerably. Examining the association
ratio distributions (Figure 5A), we also observed how GStream
outperforms CNstream and, to a greater extent, PennCNV and
QuantiSNP: while GStream ratio distribution resembles a
unimodal distribution with a high kurtosis and centred around
0.95 (i.e. precisely captured loci), the rest of the distributions from
CNstream, PennCNV and QuantiSNP showed a lower kurtosis
with more ratio values distributed between 0 and 0.75 (i.e. loci not
or poorly captured). To conclude, HumanOmi1-Quad compar-
ison, we examined the association ratio distributions stratified by
the P-value obtained by the golden standard calls (Figure S7).
GStream obtains very good results within all the P-value ranges,
with medians around 1 and decreasing interquartile ranges (from
0.2 to 0.02) as the P-value ranges decreased (i.e. greater evidence
of association). Interquartile ranges obtained by the other methods
were at least twice the obtained by GStream and increased as the
P-value ranges decreased, losing performance when comparing
higher associated loci. Poorer ratio medians were also obtained
when using the other methods.
When comparing Human1M-Duo results, the performance
differences between methods are similar to the previous compar-
ison but with an absolute decrease in performance for all the
methods due to previously referred differences on the platform
design. Despite this global performance loss, GStream was able to
precisely capture three times as many associations as PennCNV
and QuantiSNP (Figure 5B). The number of associations not
detected was also increased by a factor of 3 with respect to
HumanOmni1-Quad results (Figure S6). When analyzing
2log10P-value ratio distributions by their respective golden
standard association P-values, ratio medians were only maintained
near one when using GStream (Figure S8). Instead CNstream,
PennCNV and QuantiSNP showed a significant loss with ratio
medians below 0.5.
Copy number variation and disease susceptibility
Here we describe CNV associations that have been found by
mining two available catalogues of disease genomic associations in
order to demonstrate the power of GStream to identify new and
functionally relevant CNV disease associations.
Catalog of published genome-wide association
studies. A set of 333 SNP-CNV pairs have been identified
when searching for CNV markers in high LD with trait-associated
SNPs reported in the GWAS catalog (Table S1). From this set of
paired associations, 94 spanned the HLA region, reflecting the
known genomic complexity of this region. On the other hand,
previously reported disease-associated CNVs were detected using
Figure 4. 1KGP structural variants captured by GStream. (A) Percentage of 1KGP structural variants that are captured by GStream within
different ranges of r2 between the 1KGP calls and the GStream calls over the best marker within the respective structural variant loci. (B) Distribution
of the r2 values when more than one marker is found within the structural variant loci. Structural variants are stratified according to the best r2
obtained by all the markers covering the loci. (C) r2 distribution stratified by the frequency of the structural variation.
doi:10.1371/journal.pone.0068822.g004
Table 4. Power to detect CNP associations.
HumanOmni1-Quad Human1M-Duo Platform diff.
McCarrollA CampbellB ConradB Average McCarrollA CampbellB ConradB Average
GStream 56.40 46.80 63.87 55.69 45.09 27.65 24.38 32.37 23.32
CNstream 31.11 30.67 30.06 30.61 29.13 17.57 13.89 20.20 10.42
PennCNV 34.66 29.94 29.57 31.39 13.70 9.36 3.73 8.93 22.46
QuantiSNP 33.80 31.50 30.86 32.05 16.50 10.08 4.37 10.32 21.74
ACNV dataset provided by custom genotyping microarray-based studies.
BCNV datasets provided by CGH-based studies.
Percentage of 2log10P ratios higher than 0.9 and lower than 1.1 over the CNV population-associated regions computed for each study. Platform difference refers to the
percentage differences between HumanOmni1-Quad and Human1M-Duo platforms.
doi:10.1371/journal.pone.0068822.t004
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this approach (Table 5 and Figure S9) like, for example, well- known deletions spanning IRGM, LCE3 and ARMS2 loci, which
Figure 5. Evaluation of the power to capture genome-wide CNP association. Plots comparing Chi-square test P-values obtained with the
golden standard calls (i.e. McCarroll, Campbell and Conrad datasets) with those obtained with the four tested methods using HumanOmni1-Quad (A)
and Human1M-Duo (B) platforms. Comparison is performed by observing the distribution of the P-value association ratios (i.e. tested method versus
golden standard). A high performance difference was obtained between the two platforms tested (i.e. due to their high difference in coverage
density) and between GStream and the rest of algorithms tested.
doi:10.1371/journal.pone.0068822.g005
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have been respectively associated to Crohn’s disease [37], psoriasis
[36] and age-related macular degeneration [40]. A 45-kb deletion
near NEGR1 gene and a 50-kb deletion upstream of GPRC5B gene
previously associated to obesity and body mass index [41] were
also identified.
A thorough study of the CNVs in high LD with trait-associated
SNPs revealed several interesting loci. Some of these loci are
described below (Table 5 and Figure S10):
i. A synonymous exonic SNP rs2240335 (PADI4 gene) has been
associated to Rheumatoid Arthritis (RA) in a previous
GWAS (P-value = 2E-8) using a Japanese cohort (1247 RA
cases and 1486 controls) [42]. GStream found 12 CNV
markers 2 kb away and spanning PADI4 intron (length
= 800 bp) in high LD with rs2240335 both on CEU
(r2 = 0.82) and CHB+JPT (r2 = 0.95) HapMap populations.
ii. An intergenic SNP rs2867125 (50 kb downstream TMEM18
gene) has been associated to body mass index in previous
GWAS (P-value = 3E-49) [41]. Two CNV loci near this SNP
have been identified by GStream in high LD (r2 = 1 both on
CEU and CHB+JPT populations) with this SNP.
iii. Levels of glycated hemoglobin have been associated to the
ABCB11 intronic SNP rs552976 (P-value = 8E-18) [43]. A
deletion variant 3 kb upstream of this gene showed a high
correlation (r2 = 0.94 CEU) with the associated SNP
genotypes.
iv. Intronic SNP rs6815464 on MAEA gene has been associated
(P-value = 2E-20) with type 2 diabetes [44]. This SNP has
been found to be highly correlated with another intronic
deletion spanning ,2 kb.
v. 59UTR SNP rs6904029 (HCG9 gene) has been previously
associated with Vitiligo (P-value = 1E-21) [45]. Here we
report a CNV locus spanning the 59 region of the HCG9 gene
found in high LD with this SNP.
vi. Intronic SNP rs3077 (HLA-DPA1 gene) has been recently
associated to chronic Hepatitis B (P-value= 2E-61) on a
Japanese cohort [46]. A deletion potentially spanning three
HLA-DPA1 exons has been identified to be highly correlated
with this SNP both on the CHB+JPT and the YRI
populations.
Table 5. CNV loci highly correlated with trait-associated SNPs.
CHR SNP SNPbp CNVbp N r2CEU r2YRI r2CHBJPT pval genes GWAS_trait PMID Reported
1 rs2240335 17674537 17677196 12 0.82 0.65 0.95 2.E-08 PADI4 Rheumatoid arthritis 21505073 No
2 rs2867125 622827 623693 8 1.00 1.00 0.94 3.E-49 TMEM18 Body mass index 20935630 No
2 rs552976 169791438 169776139 5 0.94 0.26 0.32 8.E-18 ABCB11 Glycated hemoglobin
levels
20858683 No
4 rs6815464 1309901 1290281 3 1.00 0.38 0.91 2.E-20 MAEA Type 2 diabetes 22158537 No
6 rs6904029 29943067 29942384 5 1 1 0.89 1E-21 HCG9 Vitiligo 20410501 No
6 rs3077 33033022 33030885 3 0.61 0.94 1.00 2.E-61 HLA-
DPA1
Hepatitis B 21750111 No
6 rs9296736 53924697 53930407 11 1.00 1.00 0.96 3.E-09 MLIP Liver enzyme levels 22001757 No
7 rs2075671 100345106 100329189 12 0.87 0.00 0.91 1.E-09 ZAN Red blood cell count 19862010 No
19 rs7247513 12691185 12694963 13 1.00 1.00 0.81 2.E-06 ZNF490 Bipolar disorder 21254220 No
1 rs2568958 72765116 72769429 14 1.00 1.00 1.00 1.E-11 NEGR1 Body mass index 19079260 Yes
1 rs2568958 72765116 72769429 14 1.00 1.00 1.00 2.E-08 NEGR1 Weight 19079260 Yes
1 rs2815752 72812440 72769429 14 1.00 1.00 1.00 2.E-22 NEGR1 Body mass index 20935630 Yes
1 rs4085613 152550018 152557073 46 1.00 1.00 0.97 7.E-30 LCE3E;
LCE3D;
LCE3C
Psoriasis 19169255 Yes
1 rs4112788 152551276 152557073 46 1.00 0.46 0.97 3.E-10 LCE3E;
LCE3D;
LCE3C
Psoriasis 20953190 Yes
5 rs13361189 150223387 150178347 27 1.00 1.00 1.00 2.E-10 IRGM Crohns disease 17554261 Yes
5 rs1000113 150240076 150181492 13 1.00 0.39 0.91 3.E-07 IRGM Crohns disease 17554300 Yes
5 rs11747270 150258867 150203780 12 1.00 0.71 1.00 3.E-16 IRGM Crohns disease 18587394 Yes
5 rs7714584 150270420 150212972 8 1.00 0.69 1.00 8.E-19 IRGM Crohns disease 21102463 Yes
10 rs10490924 124214448 124217287 10 1.00 0.94 0.90 0.E+00 ARMS2 Age-related macular
degeneration
21665990 Yes
10 rs3793917 124219275 124216893 10 1.00 1.00 0.95 4.E-60 ARMS2 Age-related macular
degeneration
20385819 Yes
10 rs11200638 124220544 124216893 10 1.00 1.00 0.95 8.E-12 ARMS2 Age-related macular
degeneration
17053108 Yes
16 rs12444979 19933600 19949684 8 1.00 1.00 0.00 3.E-21 GPRC5B Body mass index 20935630 Yes
This table shows significant SNP-CNV pairs found in high LD. N stands for the number of CNV microarray markers correlated with the SNP genotypes, and r2CEU, r2YRI
and r2CHBJPT stand for the linkage disequilibrium measures between the SNP and the CNV. Reported GWAS P-value is also shown together with a field indicating if the
CNV association has been previously reported.
doi:10.1371/journal.pone.0068822.t005
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vii. A deletion highly correlated with intronic SNP rs9296736
(MLIP gene) has been identified spanning 5 kb MLIP intron.
This SNP has been associated with liver enzyme levels (P-
value = 3E-9) [47].
viii. Intronic SNP rs2075671 (ZAN gene) has been associated to
red blood cell count (P-value = 1E-9) on a GWAS exploring
erythrocyte phenotypes [48]. A deletion locus spanning
multiple exons of the same gene has been found with a high
correlation with the associated SNP genotypes both on the
CEU (r2 = 0.87) and the CHB+JPT (r2 = 0.91) populations.
ix. Finally, the 39UTR SNP rs7247513 (ZNF490 gene), modestly
associated with bipolar disorder (P-value = 2E-6) [49], was
also found in high LD with a 2 kb deletion covering ZNF490
intron.
A complete list of all the 333 associations can be consulted on
Table S1 and, as previously mentioned, will be regularly updated
in our website.
CNV overlap with disease-related genes. In this second
approach we examined the CNV variants called by GStream
spanning genes known to be involved in disease. A set of 149 CNV
consistent loci spanning OMIM genes were obtained (Table S2)
with a mean length of 6 kb and a mean number of 7 probes per
CNV loci.
In this analysis, well-known associated deletions were found. For
example, a common CFH haplotype with deletion of CFHR1 and
CFHR3 genes associated with lower risk of age-related macular
degeneration [50] was identified using the GStream CNV calls. A
CNV spanning CCL3L-CCL4L genes has been extensively
associated with various human immunodeficiency virus-related
outcomes [51] and was also identified in this analysis. SMN, GHR
and PKHD1 gene deletions respectively associated to spinal
muscular atrophy [52], responsiveness to growth hormone [53]
and polycystic kidney disease [54] were also detected using
GStream (Figure S11). Besides these deletions that have already
been associated to disease risk, GStream has also allowed us to
identify new exon spanning deletions within disease-associated
genes (Table S2). Some examples of these findings are the
deletions covering SLC2A9, DAZL and MBL2 gene exons.
In almost all these identified CNV loci, GStream calls across the
probes within the loci showed a high concordance demonstrating a
high performance for a high variety of CNV cluster intensity
patterns (Figure S12).
Discussion
In this study we present GStream, an integrated tool for SNP
and CNV genotyping addressed to Illumina microarray data. This
new tool has been carefully designed to obtain a high performance
in genotyping accuracy when analyzing GWAS data from
Illumina BeadChip arrays. The performance of GStream has
been assessed using reference data, extracted from the latest
releases of the 1KGP and the HapMap projects, as well as from
reference studies on CNV characterization. First, we show that
GStream has superior SNP and CNV genotyping performance
than current state-of-the-art methods. Second, we demonstrate its
power to detect new structural variation recently identified with
Next-Generation Sequencing technology. Finally, we also dem-
onstrate the utility of GStream in the identification of CNVs
within trait risk loci as well as known disease-associated genes. The
newly identified CNV associations could help to advance in the
understanding of the genetic basis of several human traits.
In a current scenario where genotyping microarrays are
decreasing in cost and widening their spectrum of analyzed SNPs
to more rare variations [55], the need of developing methods
which increase SNP genotyping accuracy is even more funda-
mental. To this end, GStream provides a way of facilitating this
success by obtaining the best performance results compared to the
available state-of-the-art methods (i.e. GenCall [34] and GenoSNP
[33]). This increased performance can be particularly meaningful
in the case of identifying rare disease-associated SNPs, tradition-
ally more exposed to genotyping errors and to the subsequent
statistical bias [56,57]. On the other hand, the accuracy of current
SNP imputation methods [58], which expand the number of
analyzed SNPs and also help to integrate the results obtained with
different microarray platforms (GWAS meta-analysis), also
depends on the quality of the originally genotyped SNPs.
Therefore, prioritizing accurate SNP genotyping methods is a
key success factor in order to obtain reliable imputation results
[59].
Besides the importance of SNPs as a source of genetic variation,
CNVs have also emerged as important variations for common trait
risk [60] as evidenced by recent GWASs [61,62,63,64,65]. In the
present study we tested our algorithm power to detect CNV loci
that have been recently identified with the Next-Generation
Sequencing technology. This NGS CNV data provided by the
1KGP includes not only previously known CNVs (i.e. detected
with CGH arrays), but also new CNV loci that have not been
previously detected. Since part of these loci are covered by
microarray probes, their detection with microarray-based tech-
nologies is therefore possible. On the other hand, previous state-of-
the-art methods for copy number genotyping [20,22] present a
lack of performance when CNVs span a few number of probes or
when intensity distributions corresponding to the different copy
number states partially overlap. The multi-component intensity
distribution models implemented in GStream will allow research-
ers to deeply scan the genome for additional CNVs, widening their
range to shorter, population-specific and/or previously unchar-
acterized CNVs.
In this study we also present a two-level comparison of the
power of GStream to detect CNV associations in a population-
based study. First, we have performed a comparison between the
different algorithms tested and, second, we have performed a
comparison between the two genotyping microarray generations
represented by the Human1M-Duo and HumanOmni1-Quad
platforms, this last one including a specific set of markers covering
known CNV loci [55]. On the one hand, we confirmed the
improvement introduced by the new generation microarrays as a
consequence not only of their major density coverage within
predefined CNV regions, but also of their improved signal quality.
The number of correctly genotyped CNV regions (i.e. character-
ized in previous reference studies) increased in ,20% when using
HumanOmni1-Quad rather than Human1M-Duo, regardless of
the CNV genotyping method being used. On the other hand,
when comparing the results obtained by each algorithm tested,
GStream showed a higher performance within all the scenarios. Its
power increase for detecting and correctly genotyping CNVs (i.e.
defined by three different reference studies based either on CGH
or custom genotyping arrays) ranges from 50% to 100% compared
with the best scoring of the other state-of-the-art methods.
Therefore, we present GStream as an integrated SNP-CNV
genotyping tool that shows a remarkable leap in performance with
respect to previous methods.
One of the most important tasks when analyzing GWAS results
is to link the associated variant to a functional effect that can
explain the disease risk association. Identifying this link is not
always easy since the identified variation can act as a proxy to the
underlying causal mutation and may not be covered by the
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microarray platform. Actually, microarray probe design is based
on the study of the linkage disequilibrium patterns and the
resulting haplotypes that are inherited in blocks [66]. In this
regard, we have identified several CNVs in high LD with SNPs
that have been previously associated to disease susceptibility. A
clear example of these linked CNVs are the IRGM1 [37] and the
LCE3B/LCE3C [36] deletions which have been associated to
Crohn’s Disease and Psoriasis, respectively. Furthermore, these
two deletions have been demonstrated to affect the expression of
the deleted genes. In addition to these previously known
associations, we have identified additional CNVs previously not
associated with the disease that could also have functional impact.
For example, several CNVs spanning hundreds of bases of gene
introns have been found to highly correlate with disease-associated
SNPs. These CNVs could provide a functional link to the
associated risk modifying, for example, RNA splicing [10,67].
Furthermore, as CNV are known to span from hundreds of
bases to multiple kilobases, it is interesting to analyze not only
those that correlate previously associated SNPs, but also those that
overlap coding sequences of genes that have been previously
associated to human disease (i.e. OMIM genes). The results from
this analysis include several known CNV associated loci, as those
spanning CFHR1/CFHR3 [65], CCL3L/CCL4L [51], SMN [52],
GHR [53] and PKHD1 [54] genes. More importantly, new
interesting CNV loci also appeared, as those spanning SLC2A9,
DAZL andMBL2 disease-associated gene exons. The SLC2A9 gene
(OMIM 606142) deletion has been identified by GStream within
eight microarray probes spanning two gene exons and two gene
introns (chr4:9,929,128-9,966,793). Since mutations within this
gene have been previously associated to uric acid concentration
[68] and to Hypouricemia [69], the functional effects of this
deletion should be further evaluated in relation to these traits.
Indeed, GLUT9LN (resulting from alternative splicing of SLC2A9
gene) is predominantly expressed in the kidney and expression
association signals reported by Doring et al. [68] link this gene to
the regulation of urate concentrations. The described exon
deletion could probably imply a similar effect by modifying the
resulting transcribed protein. On the other hand, DAZL (OMIM
601486) deletion was identified over 4 microarray probes spanning
5.8 kb (chr3:16,638,525-16,644,130). This deletion could affect
multiple gene exons resulting in a drastic functional modification.
Previous studies [70] have linked variants within this gene with
susceptibility to spermatogenic failure and therefore, this deletion
should be evaluated in the context of this human trait. GStream
also found a relevant deletion spanning the last exon of the MBL2
gene. MBL2 mutations and the consequent Mannose Binding
Lectin deficit have been previously associated with cystic fibrosis
[71] and recovery from infections [72]. This deletion could
drastically modifyMBL2 gene expression and subsequently involve
a Mannose Binding Lectin deficit whose association has also been
demonstrated.
In a time of rapidly evolving technologies and where Next-
Generation Sequencing is becoming available for the study of
common diseases, microarray-based technologies are still a
commonly used strategy to identify the genetic basis of human
traits. First, they allow the analysis of large sample collections at an
affordable cost and, second, they have anincreasing global genome
coverage, expanding their analysis scope to rarer variants.
Therefore, accurate genotyping methods are basic to discover
new associated loci that can be then further studied in more detail
using Next-Generation Sequencing. The tool that we present in
this study, GStream, provides an unprecedented accuracy when
analyzing GWAS data from previous and recent Illumina
microarray platforms. Furthermore, our software tool implemen-
tation allows large-scale GWAS projects to be analyzed in a very
short time, providing both SNP and CNV in a single analysis.
With these results, we encourage researchers conducting GWAS
on these genotyping platforms to use GStream in order to leverage
the power of their SNP and CNV loci association analyses.
Supporting Information
Figure S1 Example of raw intensity normalization. The
intensity distribution of candidate homozygote samples (i.e. AA)
across its specific allele channel (i.e. channel A) is plotted together
with its centroid scaling value as computed by Peiffer et al. [29].
GStream first weights this distribution and computes its maximum
to scale the channel intensities by the corresponding intensity
value. This example shows a typical CNV pattern where the error
produced by the first approach is magnified.
(PDF)
Figure S2 Example of how zero-threshold is computed.
(A) BAF and absolute intensities of an example marker where
some homozygous deletion samples with low intensity values can
be observed. (B) Absolute intensities are sorted and differences
between consecutive sorted intensities normalized to one. The
observed peak over these differences points to the intensity value
that will be set as threshold.
(PDF)
Figure S3 CNV labelling and scoring. (A). Category
disambiguation when the two-component model is selected. The
leftmost graph shows a case where the higher intensity component
(blue) is more frequent and it is assigned to the diploid state while
the lower intensity component (red) is assigned to the deletion
state. This assignment is due to the fact that high frequency
amplifications are very uncommon and undetectable with this
technology. The centre graph shows a case where the higher
intensity component is less frequent and homozygous deletion
samples have been found (magenta). In this case, the higher
component (blue) is assigned to the diploid state and the lower
component (red) to the deletion state fulfilling the expected Hardy-
Weinberg equilibrium frequencies. Finally, the rightmost graph
shows the last case where the higher intensity component is less
frequent and no homozygous deletion samples have been found.
In this case the higher component is assigned to the amplification
state and the lower component to the diploid state. (B) Posterior
probability of each copy number depending on the score assigned
by GStream: From 0 to 0.5 samples can be categorized as
homozygous deletion, from 0.5 to 1.5 as hemizygous deletion,
from 1.5 to 2.5 as diploid and from 2.5 to 3 as amplification.
(PDF)
Figure S4 Genotyping performance. (A) Genotyping per-
formance depending on the drop rate, where calls dropped from
the accuracy analysis were selected according to the genotype call
quality score. (B) Genotyping performance depending on the SNP
minor allele frequency. (C) Genotyping accuracy of GStream at
different sample sizes (i.e. N= 20, 40, 60, 80, 160 and 225)
compared to the accuracies obtained by GenoSNP and M3 with
the highest sample size (N= 225).
(PDF)
Figure S5 Microarray coverage density. Coverage density
of each microarray platform over the CNV regions defined by
each reference study. There are major differences between the first
Infinum HD platforms (Human610-Quad and Human1M-Duo)
and their succesors including specific CNV coverage (Hu-
man660W-Quad and HumanOmni1-Quad). Both Human610-
Quad and Human1M-Duo have a mean number of ,10 markers
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covering CNV regions, while Human660W was designed with a
highest coverage (,20 markers/region) for almost 50% of the
regions. Finally, HumanOmni1-Quad increased the global
coverage to ,20 markers/region.
(PDF)
Figure S6 Missed associations. Percentage of associations
(i.e. P-value,0.05 over the golden standard dataset) that were not
captured by the different methods tested (i.e. P-value.0.05 over
the tested method).
(PDF)
Figure S7 HumanOmni1-Quad P-value distributions.
Distributions of the P-value association ratios depending on the
golden standard dataset used for evaluation (i.e. represented by
different colours) and on the P-value range obtained over the
golden standard calls (i.e. horizontal axis).
(PDF)
Figure S8 1M-Duo P-value distributions. Distributions of
the P-value association ratios depending on the golden standard
dataset used for evaluation (i.e. represented by different colours)
and on the P-value range obtained over the golden standard calls
(i.e. horizontal axis).
(PDF)
Figure S9 Previously reported CNV associations detect-
ed by LD analysis between GStream CNV genotypes and
trait-associated SNPs. (A) LCE gene cluster deletion associated
with Psoriasis risk. (B) NEGR1 deletion associated with body mass
index. (C) IRGM deletion associated with Chrohn’s disease. (D)
ARMS2 deletion associated with age-related macular degeneration.
(E) GPRC5B upstream deletion associated with body mass index.
(PDF)
Figure S10 Interesting CNV associations detected by LD
analysis between GStream CNV genotypes and trait-
associated SNPs. (A) PADI4 gene deletion associated with
Rheumatoid Arthritis. (B) TMEM18 downstream deletion associ-
ated with body mass index. (C) 39-deletion of gene ABCB11
associated with glycated hemoglobin levels. (D) MAEA gene intron
deletion associated with type 2 diabetes. (E) HCG9 deletion
associated with Vitiligo. (F) HLA-DPA1 deletion associated with
Hepatitis B. (G) MLIP intron deletion associated with liver enzyme
levels. (H) ZAN gene deletion associated with red blood cell count.
(I) ZNF490 intron deletion associated with bipolar disorder.
(PDF)
Figure S11 GStream detected CNP loci spanning dis-
ease-related genes (OMIM) where CNVs have been
previously associated with disease. (A) CNP spanning
CFHR1 and CFHR3 previously associated to age-related macular
degeneration. (B) Deletion of GHR exon 3 that has been previously
associated with increased responsiveness to growth hormone and
Laron dwarfism. (C) Detected SMN gene deletion previously
associated with spinal muscular atrophy. (D) PKHD1 deletion
associated with polycystic kidney. (E) CCL3L1/CCL3L3 deletion
previously associated with susceptibility to HIV/AIDS.
(PDF)
Figure S12 GStream calls across consecutive markers
spanning the same CNV loci. These 6 microarray probes
cover the same CNV loci but show very different CNV intensity
patterns. GStream is completely adapted to these types of
variations and its calling procedure is able to obtain very
concordant calls when analyzing probes spanning the same CNV.
(PDF)
Table S1 CNV markers in high LD with trait-associated
SNPs reported in the GWAS catalog.
(XLSX)
Table S2 Set of 149 CNV consistent loci spanning
OMIM genes.
(XLSX)
Text S1 GStream algorithm details.
(PDF)
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